Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR)
The Lung session of the 2017 14th Banff Foundation for Allograft Pathology Conference, Barcelona focused on the multiple aspects of antibody-mediated rejection (AMR) in lung transplantation. Multidimensional approaches for AMR diagnosis, including classification, histological and immunohistochemical analysis, and donor- specific antibody (DSA) characterization with their current strengths and limitations were reviewed in view of recent research. The group also discussed the role of tissue gene expression analysis in the context of unmet needs in lung transplantation. The current best practice for monitoring of AMR and the therapeutic approach are summarized and highlighted in this report. The working group reached consensus of the major gaps in current knowledge and focused on the unanswered questions regarding pulmonary AMR. An important outcome of the meeting was agreement on the need for future collaborative research projects to address these gaps in the field of lung transplantation.
Metadata
| Organisation: | Roux, A. Pneumology, Adult CF Center and Lung Transplantation Department, Foch Hospital, Suresnes, France. Roux, A. Paris Translational Research Center for Organ Transplantation, French National institute of Health and Medical Research (INSERM). Unit UMR S970, Paris, France. Roux, A. Versailles Saint-Quentin-en-Yvelines University, UPRES EA 220, Suresnes, France. Levine, D J. Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, USA. Zeevi, A. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Hachem, R. Washington University, School of Medicine Division of Pulmonary & Critical Care, St. Louis, MO, USA. Halloran, K. Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Halloran, P F. Alberta Transplant Applied Genomics Center, University of Alberta, Edmonton, Alberta, Canada. Gibault, L. Department of Pathology, Georges Pompidou European Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. Taupin, J L. Department of Immunology and Histocompatibility, Saint-Louis Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. Neil, D A H. Department of Pathology, Queen Elizabeth Hospital, Birmingham, UK. Loupy, A. Paris Translational Research Center for Organ Transplantation, French National institute of Health and Medical Research (INSERM). Unit UMR S970, Paris, France. Adam, B A. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada. Mengel, M. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada. Hwang, D M. Toronto Lung Transplant Program, University Health Network, University of Toronto, Ontario, Canada. Calabrese, F. Department of Cardio-Thoracic and Vascular Sciences, Pathology Section, University of Padova, Italy. Berry, G. Department of Pathology, Stanford University, Stanford, CA, USA. Pavlisko, E N. Department of Pathology, Duke University Hospital, Durham, NC, USA. |
|---|---|
| Funding: | Funding not described |
| Publication type: | Guideline |
| Organ: | Lung |
| Language: | English |
| MeSH terms: | Allografts; Antibodies; Complement C4; Gene Expression Profiling; Graft Rejection; HLA Antigens; Humans; Immunohistochemistry; Isoantibodies; Lung; Lung Transplantation; Peptide Fragments; Societies, Medical; Tissue Donors; Transplantation, Homologous |